Comparing the current results to its competitors, Catalyst Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 5.63 % year on year. The sales growth was above Catalyst Pharmaceuticals Inc 's competitors' average revenue growth of 2.51 %, achieved in the same quarter.
Catalyst Pharmaceuticals Inc Net Income in the 1 quarter 2026 grew year on year by 12.33%, faster than the Catalyst Pharmaceuticals Inc 's competitors .
Catalyst Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The competitive landscape includes the anticipated entry of generic competitors for FYCOMPA® following the expiration of the '571 patent on May 23, 2025, which is expected to result in a decline in net product revenue. Royalties are paid to licensors based on net sales, with these obligations continuing until the earlier of the 12th anniversary of U.S. approval or the entry of a U.S. generic competitor. Milestone payments were earned upon DyDo receiving product approval to commercialize FIRDAPSE® in Japan. Cost of sales includes royalties payable under license agreements. Competitors identified include DyDo.
With revenue growth of 5.63 % within Overall company, Catalyst Pharmaceuticals Inc achieved improvement in market share, within Overall company to approximately 7.69 %. << More on CPRX Market Share.
*Market share is calculated based on total revenue.
August 26, 2025
In a notable development for the pharmaceutical industry, Catalyst Pharmaceuticals Inc. recently announced a settlement with Lupin Pharmaceuticals concerning the patent litigation of FIRDAPSE (amifampridine). This settlement has substantial implications not only for both companies involved but also for the broader market, especially considering that Catalyst s share performance has lagged relative to the overall market over the past month. This article aims to examine the settlement agreement, its potential market ramifications, and the performance dynamics of Catalyst Pharmaceuticals. Patent Settlement Overview Catalyst Pharmaceuticals and Lupin Pharmaceuticals have reached a settlement regarding the pa...
January 21, 2025
Catalyst Pharmaceuticals Inc. recently celebrated a significant milestone with its sub-licensee DyDo Pharma s successful launch of FIRDAPSE in Japan. This introduction marks a crucial step for Catalyst as it continues to expand its footprint in the global pharmaceutical landscape. FIRDAPSE, indicated for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), has been gaining traction in various markets, and Japan s launch underscores the growing demand for innovative therapies in rare diseases.While this launch represents a triumph for Catalyst, the company s financial performance in the third quarter of 2024 reveals a more complex narrative. On a trailing twelve-month basis, Catalyst s income per employ...
July 24, 2024
Catalyst Pharmaceuticals Inc., a renowned biopharmaceutical company specializing in developing and commercializing groundbreaking medicines for rare and challenging diseases, recently announced a significant milestone in their pursuit of treating Duchenne Muscular Dystrophy (DMD) and other indications. The company has entered into a License, Supply, and Commercialization Agreement with Kye Pharmaceuticals Inc., granting Kye exclusive rights to market AGAMREE (vamorolone), a novel corticosteroid, in the Canadian market. This strategic partnership aims to address the unmet medical needs of DMD patients while expanding Kye s portfolio in Canada.The Alliance between Catalyst Pharmaceuticals and Kye Pharmaceutica...
Mink Therapeutics Inc is a biotechnology company that focuses on developing mRNA therapeutics for treating genetic diseases. Their business model primarily revolves around utilizing messenger RNA (mRNA) to develop and deliver novel therapies that can address genetic disorders. By leveraging the potential of mRNA technology, Mink Therapeutics aims to offer innovative treatments that have the ability to fundamentally transform the field of genetic medicine.
Kamada Ltd is a biopharmaceutical company that operates on a business model centered around developing and commercializing specialty plasma-derived therapeutics. The company focuses on leveraging its expertise in proprietary protein purification technology and plasma collection to produce and deliver high-quality therapeutic products. Kamada aims to address unmet medical needs in various therapeutic areas, providing innovative treatment options to patients worldwide.
Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.
Nls Pharmaceutics Ltd is a pharmaceutical company with a business model centered around research, development, and commercialization of innovative drug therapies. They focus on designing and formulating novel drug delivery systems that improve the efficacy and safety of existing medications. Nls Pharmaceutics aims to bring their advanced drug delivery technologies to market by partnering with larger pharmaceutical companies or seeking regulatory approval for their own products.
Sources:
Catalyst Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Catalyst Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
